Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2009 September;61(3) > Minerva Urologica e Nefrologica 2009 September;61(3):249-56

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984


eTOC

 

  ACUTE KIDNEY INJURY


Minerva Urologica e Nefrologica 2009 September;61(3):249-56

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium

Ecke T. H. 1, Gerullis H. 2, Bartel P. 1, Koch S. 3, Ruttloff J. 1

1 HELIOS Hospital, Department of Urology,Bad Saarow, Germany 2 Lukas Hospital, Department of Urology,Neuss, Germany 3 HELIOS Hospital, Institute of Pathology,Bad Saarow, Germany


PDF  


Aim. The objective of this study was to evaluate the adjuvant chemotherapy with gemcitabine, paclitaxel, and cisplatin for urothelial carcinoma.
Methods. Twenty-seven patients with invasive transitional cell carcinoma of the urothelium were treated between 2001 and 2007. All patients received chemotherapy with intravenous gemcitabine at a dose of 1000 mg/mÇ on Days 1 and 8, intravenous paclitaxel at a dose of 80 mg/mÇ on Days 1 and 8, and intravenous cisplatin at a dose of 50 mg/mÇ on Day 2. Treatment courses were repeated every 21 days.
Results. Median follow-up period was 32.5 months. Six patients came to progressive disease. The median overall survival was not reached, and the actuarial 1-year and 2-year survival rates were 89% and 67% respectively. The median progression-free survival was 10.0 months. Median survival time for patients with ECOG status 0, and 1 was 52.0, and 22.0 months respectively. Grade 4 neutropenia occurred in 18.5% of patients, but there was no treatment related mortality.
Conclusion. The combination of gemcitabine, paclitaxel, and cisplatin is a highly effective and tolerable regimen for patients with invasive transitional cell carcinoma of the urothelium. This treatment should be considered as a suitable option that deserves further prospective evaluation. ECOG performance status is an important predictive factors for survival.

top of page

Publication History

Cite this article as

Corresponding author e-mail